Project Grant R01DK145857
Award Date 8/15/26
Completion Date 7/31/30
Dollars Obligated $519K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02139, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Massachusetts Institute of Technology $100,228 on May 1, 2027, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop and apply synthetic biology tools to engineer vascularized human liver tissues capable of dynamically responding to regenerative stimuli. The project establishes closed-loop synthetic gene circuits regulating proangiogenic and hepatoprotective growth...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $814,500 to the University of Pittsburgh on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to fund research dissecting functional decompensation of end-stage liver disease and investigating the mechanism and impact of transcription factors on long-term functional reprogramming. The research examines how the transcription factor HNF4A—which controls...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Massachusetts General Hospital $850,096 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of S100A9+ macrophages and monocytic myeloid-derived suppressor cells in driving liver fibrosis in metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD/MASH). The research leverages advanced multi-omics...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Boston Medical Center Corporation $3.517 million on September 4, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to evaluate induced pluripotent stem cell-derived endothelial cell therapy for liver disease. The research will assess the therapeutic potential of iPSC-derived endothelial cells to promote liver regeneration and alleviate liver disease. The approach...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Texas Health Science Center at Houston $158,220 on May 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of neutrophil-derived HIF1A signaling in hepatic ischemia/reperfusion injury. The research addresses mechanisms of graft dysfunction following liver transplantation, a leading cause of poor outcomes in end-stage liver...
- The National Institute of Diabetes and Digestive and Kidney Diseases, a component of the Department of Health and Human Services, awarded Virginia Commonwealth University $421,744 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the regulation of liver regeneration by hepatocyte-derived extracellular vesicles. The project will characterize the role of microRNAs carried by hepatocyte-derived extracellular vesicles...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Washington $839,388 on August 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop engineered human liver tissue for heterotopic transplant and therapeutic rescue of liver disease. The project addresses the critical shortage of donor organs for patients with end-stage liver disease by developing cultured human hepatocytes as organoids that...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded New York University $1,677,898 on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop fat and iron-corrected quantitative MRI T1 mapping as a non-invasive biomarker for evaluating chronic liver disease, particularly metabolic-associated steatohepatitis (MASH). The project addresses the clinical need for non-invasive assessment of liver pathology...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Weill Medical College of Cornell University $585,556 on August 10, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate endothelial metabolic control of liver homeostasis and response to damage. The research examines how liver sinusoidal endothelial cells (LSECs) lose their specialized phenotype during liver fibrosis through a process called capillarization,...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Trustees of Boston University $100,228 on February 1, 2027, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to evaluate the therapeutic potential of induced pluripotent stem cell–derived endothelial cell (IEC) therapy for promoting liver regeneration in acute liver injury. The research will establish protocols for generating pure populations of iPSC-derived endothelial...